Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12633753 | 0.85 | KMT2A (0.64) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL1860255 | 0.85 | PKM (0.61) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL10732353 | 0.83 | POLB (0.59) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL28856266 | 0.83 | KMT2A (0.62) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL26649089 | 0.81 | KMT2A (0.60) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL21826933 | 0.81 | KMT2A (0.67) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL31052720 | 0.81 | PKM (0.60) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL2661411 | 0.81 | PKM (0.52) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL1107514 | 0.80 | PKM (0.55) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL31738248 | 0.79 | PKM (0.97) | PKMKMT2ALMNAGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025242880-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE | MY-T BIO LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119486992-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024184520-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| EP-4347568-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | Protego Biopharma, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | THE SCRIPPS RESEARCH INSTITUTE | 2024-03-21 | — | — | US | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022251533-A1 | HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS | PROTEGO BIOPHARMA, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2021158638-A1 | ARYLAZO-HETEROARYL COMPOUNDS AND THEIR USE FOR LONG-TERM THERMAL ENERGY STORAGE | BRANDEIS UNIVERSITY (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | PKM 1916/4885KMT2A 2974/4885LMNA 2874/4885 |
| US-20240092757-A1 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | XBP1, HSPA5, DNAJC10 | PKM 3288/4885KMT2A 4215/4885LMNA 1839/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | PKM 2081/4885KMT2A 3086/4885LMNA 4174/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PKM 2336/4885KMT2A 114/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.